Titlebook: ;

空隙

書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives影響因子(影響力)




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives影響因子(影響力)學(xué)科排名




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives網(wǎng)絡(luò)公開度




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives被引頻次




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives被引頻次學(xué)科排名




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用學(xué)科排名




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives讀者反饋




書目名稱Group-Sequential Clinical Trials with Multiple Co-Objectives讀者反饋學(xué)科排名

簡潔

FIN

euphoria

Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints,wo interventions based on two primary endpoints. In this situation, there are many procedures for controlling the Type I error rate. We discuss the simplest procedure, i.e., the weighted Bonferroni procedure which is commonly applied in practice. We evaluate the behavior of the sample size, power, a

爆炸

B-cell

Future Developments,her design features. This includes clinical trials with more than two interventions (e.g., dose-selection clinical trials): trials with time-to-event endpoints and trials with targeted subgroups and enrichment clinical trial designs. In Chap. ., we briefly discuss the issues in the design of these t

B-cell

平息

MENT

Philanthropy and Settler Colonialismuss several decision-making frameworks for evaluating efficacy or futility based on boundaries using group-sequential methodology. We incorporate the correlations among the endpoints into the calculations for futility critical boundaries and evaluate the required sample sizes as a function of design

FICE